Nervous Disorder TRIZ Cases

Measuring pro-neurotensin 1-117 addresses insufficient specificity of traditional markers for female cardiovascular event prediction.

MgluR5 antagonists interrupt BMAA-induced PP2A phosphorylation, addressing the complex molecular mechanisms driving abnormal tau accumulation and dementia.

ApoE-mimetic peptides cross the blood-spinal cord barrier, reducing glial activation and secondary tissue damage while improving motor function.

Administering VEGF alongside G-CSF and SCF polypeptides restores neurogenesis and improves cerebral blood flow to treat CADASIL.

Segmented toxin domains reduce immune responses while promoting neuronal growth.

A sulfonamidoacetamide compound selectively inhibits gamma-secretase to reduce beta-amyloid peptide levels in brain and plasma.

Fluorinated proline analogs lock Xaa-Pro peptide bonds into fixed cis or trans states to generate conformation-specific antibodies.

Formula I and II compounds displace inhibitors to resolve inadequate eIF2α modulation in beta-thalassemia treatment.

Specific amino acid sequences bind to Taq polymerase, maintaining function at elevated temperatures without refrigeration.

Huperzine A manages neuropathic pain and epilepsy by blocking NMDA receptors and inhibiting acetylcholinesterase, reducing side effects from conventional drugs.

A lentiviral vector delivers the ABCD1 gene to hematopoietic stem cells.

Neurotoxin derivative delivers single chain antibodies into neuronal cytosol, resolving toxicity and specificity issues in intracellular targeting.

Intranasal neuropeptide Y delivery bypasses the blood-brain barrier to treat mood disorders.

Fully human antibodies bind c-Met receptors to inhibit tumor growth, resolving suboptimal clinical attributes of prior therapeutic agents.

Assessing plasmablast counts identifies nonresponsive relapsing-remitting multiple sclerosis patients to prevent adverse reactions and select IL-6 inhibitors.

A pharmaceutical conjugate links insulin to saccharide ligands and a fatty chain framework.

Mutated SDF-1 peptides resist MMP-2 digestion, preserving chemoattractant activity to attract T cells and enhance cardiac tissue repair.

Memantine modulates NMDA receptor activity to treat neuropsychiatric disorders linked to GRIN2A mutations.

Segmenting antibody structures into compact variable domains enables deep tumor penetration and reduces dosing frequency compared to full-size agents.

SEMA4D binding molecules reduce blood-brain barrier permeability by blocking SEMA4D-Plexin-B1 signaling in neuroinflammatory disorders.

Conformation-selective binding agents stabilize muscarinic acetylcholine receptors to resolve crystallization challenges of active-state conformations.

Retinoic acid and gemfibrozil enhance lysosomal biogenesis to degrade amyloid-beta aggregates, reducing plaque load in Alzheimer's disease.

Polysorbate minimizes thioflavin derivative retention on silicone tubing during sterile filtration.

Intein-mediated splicing joins split Cas9 portions delivered by separate rAAV vectors, overcoming packaging limits for precise genome editing.

Administers uridine alongside ketone esters or salts to suppress spike wave discharges in absence epilepsy, bypassing traditional drug compliance limits.

Modified calcitonin gene-related peptide antagonists inhibit receptor activity, resolving limited in vivo efficacy.

Zinc finger nucleases integrate transgenes into the albumin gene locus to produce therapeutic enzymes.

Dried whole coffee fruit extraction recovers peel antioxidants to decrease amyloid-beta deposition while preventing mycotoxin contamination risks.

AAV9 vectors carrying codon-optimized sulfamidase sequences cross the blood-brain barrier to correct neurological symptoms in mucopolysaccharidosis type IIIA.

Monoclonal antibodies target Aβx-37 peptides via hybridoma production for precise immunoassay detection.

A pharmaceutical composition combines curcumin, N-acetyl-L-carnitine, and alpha-lipoic acid to deliver neuroprotective effects.

Bicycloheteroaryl-heteroaryl-benzoic acid compounds selectively activate retinoic acid receptor beta 2 to promote neurite development.

Intravenous recombinant ALDH2 enzyme reduces toxic aldehyde levels, preventing organ damage and fatalities from alcohol poisoning.

Specific compounds inhibit E1 activating enzymes, blocking ubiquitin-like conjugation pathways to treat cell proliferation disorders.

EP2 receptor antagonists inhibit PGE2-induced activation to reduce neurotoxicity.

Formula I compound activates D3 receptors via allosteric binding, avoiding D2 cross-reactivity that causes impulse control disorders.

Segmenting the Shank3 sequence into essential domains creates a miniaturized protein that fits within AAV packaging limits while rescuing behavioral deficits.

Clonal iPSC-derived neural progenitor cells uniformly express GDNF via tetracycline-inducible promoters, replacing heterogeneous fetal tissue sources.

Selective ERβ ligands resolve the contradiction between therapeutic efficacy and adverse side effects while enhancing blood-brain barrier penetration.

Asymmetric amino acid modifications in the lower hinge region of an IgG Fc construct reduce binding to Fcγ receptors and C1q protein.

Anti-G-CSFR antibodies block receptor activation to prevent inflammatory exacerbation while maintaining neutrophil production.

BRD7 antagonists remove inhibitory signals to regenerate CNS cells, addressing neurodegenerative disease root causes.

Isolating specific cinnamic acid derivatives eliminates fluctuating effectiveness from herbal extracts, enabling precise dosing.

SV2A inhibitors modulate synaptic function to improve spatial memory retention in aging subjects.

Amphipathic peptides exploit electrostatic attraction to selectively destroy cancer cells while sparing healthy tissue.

Fermented papaya preparation treats electrohypersensitivity by normalizing brain blood flow despite unclear EMF mechanisms.

PEGylated CGRP peptide antagonists mask immunogenic epitopes and reduce plasma clearance, providing sustained migraine treatment with reduced side effects.

Recombinant expression vectors with dual suicide genes selectively eliminate tumorigenic cells while preserving therapeutic stem cells.